scholarly journals Stereotactic body radiotherapy for pulmonary oligometastases as an initial metastasis‐directed therapy: patterns of relapse and predictive factors for early mortality

2021 ◽  
Author(s):  
Takaya Yamamoto ◽  
Yuzuru Niibe ◽  
Masahiko Aoki ◽  
Hiroshi Onishi ◽  
Kazunari Yamada ◽  
...  
Keyword(s):  
Predictive Factors ◽  
Stereotactic Body Radiotherapy ◽  
Early Mortality ◽  
Initial Metastasis

scholarly journals Predictive Factors of Early Mortality after Living Donor Liver Transplantation: A Single Center Experience of 780 Cases over 16 Years

2021 ◽  
Vol 26 (1) ◽  
pp. 52
Author(s):  
Mohamed Abdel Wahab ◽  
Ahmad Mohamed Sultan ◽  
Amr Yasesn ◽  
Omar Fathi ◽  
Tarek Salah ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Predictive Factors ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Early Mortality ◽  
Single Center ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Single Center Experience

Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3560-3560
Author(s):  
Toshiki Masuishi ◽  
Toshikazu Moriwaki ◽  
Shota Fukuoka ◽  
Atsuo Takashima ◽  
Yosuke Kumekawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Multivariate Analysis ◽  
Mortality Rate ◽  
Metastatic Colorectal Cancer ◽  
Predictive Factors ◽  
Univariate Analysis ◽  
Tumor Resection ◽  
Early Mortality ◽  
Cox Proportional Hazards Model ◽  
P Value

3560 Background: Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognized as standard treatments for patients (pts) with refractory metastatic colorectal cancer (mCRC). Because these drugs have limits on efficacy benefit for some pts, we are necessary to select pts who may be better not to receive REG or FTD/TPI. However, no reports are available on how to predict pts with early mortality after initiation of these drugs. Methods: We retrospectively evaluated pts with mCRC who were registered in a multicenter observational study (the REGOTAS study). The main inclusion criteria were ECOG PS of 0–2, refractory or intolerant to fluoropyrimidines, oxaliplatin, irinotecan, and anti-VEGF and anti-EGFR therapy (if KRAS wild type), and no prior use of REG or FTD/TPI. Predictive factors for early mortality (≤ 12 weeks from initiation of REG or FTD/TPI) were evaluated by multivariate analysis for survival with all variables with P values of <0.05 from the univariate analysis, using the Cox proportional hazards model. In this analysis, the pts who lived at first 15 weeks were defined as censored case. Results: A total of 523 pts (REG, 212; FTD/TPI, 311) were eligible. Predictive factors for early mortality were without primary tumor resection [adjusted hazard ratio (aHR), 1.56; p = 0.02], the low level of albumin (aHR, 2.31; p < 0.0001), the high level of CRP (aHR, 2.31; p < 0.0001), and short time from diagnosis of mCRC (aHR, 1.77; p = 0.002) by multivariate analysis. The pts harboring all these poor factors were classified into the high (H) risk of early mortality group. Two groups of pts with H and non-H were identified, with 12-week mortality rate of 39 and 14%, with 14-week mortality rate of 70 and 18%, and with median survival time (MST) of 2.9 and 7.8 months, respectively (HR of H/non-H, 4.02; p value < 0.0001). In pts treated with REG, H and non-H groups had 12-week mortality rate of 38 and 16%, 14-week mortality rate of 79 and 18%, and MST of 2.8 and 7.8 months, respectively. In pts treated with FTD/TPI, H and non-H groups had 12-week mortality rate of 41 and 13%, 14-week mortality rate of 63 and 18%, and MST of 3.2 and 7.7 months, respectively. Conclusions: Our predictive model for early mortality after initiation of REG or FTD/TPI might be useful for selecting pts who should not receive either these drugs.

scholarly journals Clinical Features and Predictive Factors of Early Mortality in Patients with MM Outside of Clinical Trials

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5593-5593
Author(s):  
Hiroki Kobayashi ◽  
Yoshiaki Abe ◽  
Daisuke Miura ◽  
Kentaro Narita ◽  
Akihiro Kitadate ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
High Risk ◽  
Predictive Factors ◽  
Real World ◽  
Medical Center ◽  
Early Mortality ◽  
Novel Agents ◽  
Predictive Score ◽  
Ecog Ps

Abstract Background Novel agents such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have improved the overall survival of patients with newly diagnosed multiple myeloma (NDMM) over the last decade. However, early mortality (EM) remains a serious obstacle for a portion of the patients despite receiving novel agents. The report based on clinical trials showed that age, International Staging System (ISS), lactate dehydrogenase (LDH) levels, and high-risk cytogenetic abnormalities (CA) predict EM due to myeloma progression. The result, however, may differ from real-world settings because the patients of clinical trials are relatively younger and have fewer health problems, and the major cause of EM is not only disease progression, but also infections and comorbidities. In this study, we retrospectively analyzed the clinical variables that affected EM in patients with multiple myeloma (MM) in the real-world setting in the novel agent era. Patients and Methods The study population consisted of 238 consecutive patients with NDMM between January 2008 and April 2018 at Kameda Medical Center, Japan. All patients were administered PI- or IMiD-based combined chemotherapy in the frontline setting. Patients diagnosed with smoldering MM and solitary plasmacytoma and who did not receive treatment were excluded in this study. Early mortality was defined as death within two years after diagnosis due to any cause. Comorbidities were evaluated according to the Charlson Comorbidity Index (CCI). Instrumental Activities of Daily Living (IADLs) were retrospectively scored based on medical records. IADLs were assessed by the percentage of the score because the full score of IADLs is different between men and women. High-risk CA was defined by the presence of t(4;14), t(14;16), and del(17p). Statistical analyses were performed with EZR, which is a graphical user interface for R ver. 3.2.2. Ethical considerations This study was approved by the institutional review board of Kameda Medical Center and conducted according to the principles of the Declaration of Helsinki. Results The median age of the patients was 72.2 years, and the median observation period was 40.8 months. Fifty patients (21.3%) died within two years. The major causes of mortality were myeloma progression (36%), infection (22%), and comorbidities (20%). Baseline involved free light chain (iFLC), LDH > normal range, and high-risk CA were not statistically significant between the patients with or without EM. There were significant differences in age, reduction in iFLC on day 7 from the baseline, ISS stage, Revised-ISS stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥3, CCI score ≥4, and the percentage of IADL scores between the two groups (Table1). Next, we analyzed IADL scores and the reduction in iFLC on day 7 because these variables were not assessed in previous studies. Receiver-operating characteristic curve analysis showed that the best cutoff values were 50% for IADL scores and 65% for the reduction in iFLC on day 7. Univariate analysis suggested that the factors associated with EM were age >75 years, ISS stage 3, CCI score ≥4, ECOG-PS ≥3, IADL <50%, and iFLC reduction >65% on day 7. The multivariate analysis showed that CCI score ≥4 [odds ratio (OR), 2.43; 95% confidence interval (CI), 1.11-5.32; p=0.027], IADL score <50% (OR, 3.31; 95% CI, 1.42-7.70; p=0.006), and iFLC reduction >65% on day 7 (OR, 3.20; 95% CI, 1.45-7.07, p=0.004) were independent predictive factors for EM (Table2). Thus, the EM predictive score was established according to following variables: CCI score ≥4, IADL score <50%, iFLC reduction >65% on day 7, and ISS stage 3. Sixty patients were categorized with high scores (score ≥3), and half of the patients with high scores died within two years, while only 10% of the patients with low scores (score <3) died within two years (p<0.001). Conclusion One-fifth of the patients with NDMM died within two years due to myeloma progression, infection, and comorbidities. Our results suggested that high-risk CA and high levels of LDH did not have predictive value for EM in patients with NDMM outside of clinical trials. The presence of high CCI scores, low IADL scores, and decreases in iFLC (>65%) on day 7 from the baseline were independent prognostic factors, which could reflect both patient and disease factors. The combination of the CCI score, IADL score, ISS stage, and early reduction in iFLC may help in the identification of EM. Disclosures No relevant conflicts of interest to declare.

Predictive Factors for Early Mortality After Percutaneous Endoscopic and Radiologically-Inserted Gastrostomy

2013 ◽  
Vol 58 (12) ◽  
pp. 3558-3565 ◽  
Author(s):  
Faidon-Marios Laskaratos ◽  
Martin Walker ◽  
Mary Walker ◽  
Janitha Gowribalan ◽  
Despoina Gkotsi ◽  
...  
Keyword(s):  
Predictive Factors ◽  
Early Mortality

scholarly journals Predictive Factors for Early Mortality after Hepatic Resection for Hepatitis C Virus Related Hepatocellular Carcinoma: A Single Center Experience

2020 ◽  
Vol 88 (12) ◽  
pp. 2261-2268
Author(s):  
AHMED FAROUK, M.D.; AHMED SHEHTA, M.D. ◽  
AHMAD MOHAMED SULTAN, M.D.; MOHAMED ELSHOBARY, M.D. ◽  
RAMI SAID, M.D.
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatic Resection ◽  
Predictive Factors ◽  
Early Mortality ◽  
Single Center ◽  
Single Center Experience

Predictive factors for early mortality after percutaneous endoscopic gastrostomy

1995 ◽  
Vol 42 (4) ◽  
pp. 330-335 ◽  
Author(s):  
Victoria L. Light ◽  
Frederick A. Slezak ◽  
Joel A. Porter ◽  
Lowell W. Gerson ◽  
Gary McCord
Keyword(s):  
Percutaneous Endoscopic Gastrostomy ◽  
Predictive Factors ◽  
Early Mortality ◽  
Endoscopic Gastrostomy

Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score

Heart ◽  
2014 ◽  
Vol 100 (13) ◽  
pp. 1016-1023 ◽  
Author(s):  
Bernard Iung ◽  
Cédric Laouénan ◽  
Dominique Himbert ◽  
Hélène Eltchaninoff ◽  
Karine Chevreul ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Predictive Factors ◽  
Early Mortality ◽  
Individual Risk ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Individual Risk Assessment ◽  
Valve Implantation
Sign in / Sign up

Export Citation Format

Share Document